Clinical Trial Results:
Phase II Study of Dasatinib (BMS-354825) for Advanced ‘Triple-negative’ Breast Cancer
+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 16-Aug-06)
+ Pharmacogenomics Tissue Sample Amendment Number 02 - Site Specific - (version 1.0 dated 16-Aug-06)
Summary
|
|
EudraCT number |
2006-002045-36 |
Trial protocol |
FR BE IT |
Global completion date |
09 Sep 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Dec 2016
|
First version publication date |
24 Dec 2016
|
Other versions |
|
Summary report(s) |
CA180-059_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.